Samcheondang Pharmaceutical is seeing a surge in trading volume, attracting investors' attention during the morning session on the 10th. In the market that day, buying interest is flowing into Samcheondang Pharmaceutical as expectations for the overall biotech industry and specific catalysts for individual stocks are highlighted. In particular, the triggering of the Volatility Interruption (VI) mechanism during the session concentrated market attention. According to the Korea Exchange, Samcheondang Pharmaceutical exhibited expanding short-term volatility, with a static VI triggered and subsequently lifted that morning.

Recently, global financial markets have faced a new variable: escalating military tensions between the United States and Iran. Following an armed conflict in the Middle East, expectations of a U.S. military response have increased volatility in international oil and commodity markets. Iran is also maintaining a hardline stance, putting investors on high alert.

However, in the domestic stock market, selective buying is flowing into growth industries despite geopolitical anxieties. The biotech sector is also maintaining steady investor interest based on expectations for new drug development, technology exports, and global market expansion.

Samcheondang Pharmaceutical is a company pursuing a growth strategy centered on ophthalmic disease treatments and biosimilar businesses. The market is closely watching the company's potential for global market expansion and its research and development (R&D) results, viewing future business progress as a crucial variable that will determine its corporate value.

The securities industry assesses that while instability in the Middle East may shrink the appetite for risk assets across the entire financial market, the core determinants of stock prices in the biotech sector are individual companies' R&D achievements and commercialization potential. Therefore, clinical results and business performance may act as more critical variables than the international political landscape.

Meanwhile, market participants are keeping an eye on the possibility of further clashes between the U.S. and Iran, alongside the global interest rate environment, changes in biotech investment sentiment, and Samcheondang Pharmaceutical's business progress. While volatility may expand in the short term, evaluations of the company's performance and growth potential are expected to dictate the stock's trajectory in the mid to long term.

[※ This article was written for the purpose of providing investment information, and investment decisions and responsibilities lie solely with the investor. AI was partially utilized in the writing process of this article.] [This article is by no means a solicitation for investment. The content may merely be an opinion, so please do not use it as a reference or data for investing. All investments are made by individual choice and judgment, and the final responsibility lies with the investor. This publication assumes absolutely no responsibility.]